Latham, Davis Polk Guide Cancer Biotech's $150M IPO Launch
Oncology-focused biotechnology firm Revolution Medicines Inc. on Monday set a price range for an estimated $150 million initial public offering to fund cancer therapies under development, guided by Latham & Watkins...To view the full article, register now.
Already a subscriber? Click here to view full article